Our Take
Journavx proves the science works but commercial execution remains the bottleneck for non-opioid pain drugs.
Why it matters
Biotech investors need proof that ion channel blockers can scale commercially before committing to the next wave of pain startups. Vertex's struggle with a validated target suggests the problem isn't just scientific.
Do this week
Pain-focused biotech investors: audit your portfolio companies' commercial strategies before the chronic pain readouts in 2027 reset market expectations.
Journavx hits $90M but misses Wall Street targets
Vertex's Journavx generated just under $90 million in its first year on the market (company-reported), falling below analyst forecasts for most of that period. The drug surpassed 1 million total prescriptions by April 2025, with doctors using it after procedures from knee replacements to wisdom tooth extractions.
The launch drove Vertex's overhead costs up 20%, adding almost $300 million in expenses (per company earnings). Vertex doubled its Journavx sales force from 150 to 300 representatives and deployed TV, Instagram, and YouTube ads plus athlete partnerships with Jayson Tatum and Alex Smith.
Journavx failed a sciatica study last summer, narrowing its path to the chronic pain market. Its future in that space now depends on a late-stage diabetic nerve pain trial with results expected in 2027.
Ion channel investing faces a prove-it moment
Pain drug research attracted fresh investment after Journavx's March 2025 launch. Latigo Biotherapeutics raised $150 million (company-announced), while Eli Lilly acquired SiteOne Therapeutics for up to $1 billion. Xenon Pharmaceuticals stock surged 60% over 12 months on epilepsy data and pain pipeline progress.
But the commercial reality is sobering. "Certainly, people don't feel as bullish about the drug as they did a year ago," said Stifel analyst Paul Matteis. The muted performance comes despite Journavx being the first truly innovative pain medication approved in the U.S. in over two decades.
Researchers are already pivoting to combination approaches. Harvard studies found some neurons continue firing pain signals even when NaV1.8 activity is nearly eliminated, suggesting single-target drugs hit a ceiling. Vertex is advancing NaV1.7 inhibitors to use alone or paired with NaV1.8 blockers.
Chronic pain approval remains the real test
Acute pain prescriptions are inherently short-term, requiring enormous scale to drive meaningful revenue. The chronic pain market affects one in four Americans and represents the true commercial prize, where long-term opioid use creates the strongest demand for alternatives.
Vertex holds $13 billion in cash and generates $3 billion quarterly from cystic fibrosis drugs, giving it runway smaller biotechs lack. The company will reduce free drug giveaways next year to improve margins per sale, but analysts view this as minor compared to potential chronic pain revenue.
At least six companies are pursuing NaV1.7 programs, with Vertex and SiteOne collaborating on dual-target approaches. The controlled combination strategy reflects growing consensus that "we're not looking for a dirty drug so much as a controlled mess," as Yale neurology professor Stephen Waxman describes it.